Original articles
Yisheng He, Jiang Ma, Xiaoyu Fan, Liang Ding, Xinxin Ding, Qing-Yu Zhang, Ge Lin. The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3820-3835

The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity
Yisheng Hea, Jiang Maa, Xiaoyu Fanb, Liang Dingb, Xinxin Dingb, Qing-Yu Zhangb, Ge Lina
a. School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong SAR 999077, China;
b. Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
Abstract:
Pyrrolizidine alkaloids (PAs) are the most common phytotoxins with documented human hepatotoxicity. PAs require metabolic activation by cytochromes P450 to generate toxic intermediates which bind to proteins and form protein adducts, thereby causing cytotoxicity. This study investigated the role of the gut–liver axis in PA intoxication and the underlying mechanisms. We exposed mice to retrorsine (RTS), a representative PA, and for the first time found RTS-induced intestinal epithelium damage and disruption to intestinal barrier function. Using mice with tissue-selective ablation of P450 activity, we found that hepatic P450s, but not intestinal P450s, were essential for PA bioactivation. Besides, in RTS-exposed, bile duct-cannulated rats, we found the liver-derived reactive PA metabolites were transported by bile into the intestine to exert enterotoxicity. The impact of gut-derived pathogenic factors in RTS-induced hepatotoxicity was further studied in mice with dextran sulfate sodium (DSS)-induced chronic colitis. DSS treatment increased the hepatic endotoxin level and depleted hepatic reduced glutathione, thereby suppressing the PA detoxification pathway. Compared to RTS-exposed normal mice, the colitic mice displayed more severe RTS-induced hepatic vasculature damage, fibrosis, and steatosis. Overall, our findings provide the first mode-of-action evidence of PA-induced enterotoxicity and highlight the importance of gut barrier function in PA-induced liver injury.
Key words:    Pyrrolizidine alkaloid    Cytochrome P450    Inflammatory bowel disease    Intestinal injury    Liver injury    Gut–liver axis   
Received: 2021-04-06     Revised: 2021-06-12
DOI: 10.1016/j.apsb.2021.07.013
Funds: This work was supported by Research Grants Council of Hong Kong Special Administrative Region (GRF Project Nos. 14160817 and 14106318 to Ge Lin, China), and a grant from the National Institutes of Health (No. R01 GM082978 to Qing-Yu Zhang, USA). We thank Ms. Weizhu Yang for assistance with mouse breeding and genotyping analysis, Dr. Lei Yin and Dr. Xiangmeng Wu for assistance with analytical instruments, and Dr. Weiguo Han and Dr. Nataliia Kovalchuk for assistance with histological assays.
Corresponding author: Qing-Yu Zhang,E-mail:qyzhang@pharmacy.arizona.edu;Ge Lin,E-mail:linge@cuhk.edu.hk     Email:qyzhang@pharmacy.arizona.edu;linge@cuhk.edu.hk
Author description:
Service
PDF(KB) Free
Print
0
Authors
Yisheng He
Jiang Ma
Xiaoyu Fan
Liang Ding
Xinxin Ding
Qing-Yu Zhang
Ge Lin

References:
[1] Jank B, Rath J. The risk of pyrrolizidine alkaloids in human food and animal feed. Trends Plant Sci 2017;22:191-193
[2] Robertson J, Stevens K. Pyrrolizidine alkaloids: occurrence, biology, and chemical synthesis. Nat Prod Rep 2017;34:62-89
[3] Lin G, Wang JY, Li N, Li M, Gao H, Ji YA, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 2011;54:666-673
[4] Zhu L, Zhang CY, Li DP, Chen HB, Ma J, Gao H, et al. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin 2020. Available from: https://doi.org/10.1038/s41401-020-00553-9
[5] Prakash AS, Pereira TN, Reilly PEB, Seawright AA. Pyrrolizidine alkaloids in human diet. Mutat Res-Gen Tox En 1999;443:53-67
[6] He Y, Shi M, Wu X, Ma J, Ng KT, Xia Q, et al. Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology 2021. Available from: https://doi.org/10.1002/hep.31723
[7] Ruan J, Yang M, Fu P, Ye Y, Lin G. Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol 2014;27:1030-1039
[8] Ma J, Ruan J, Chen X, Li D, Yao S, Fu PP, et al. Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 2019;32:1027-1039
[9] Lin G, Cui YY, Hawes EM. Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos 1998;26:181-184
[10] Lame MW, Jones AD, Morin D, Segall HJ, Wilson DW. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat. Drug Metab Dispos 1995;23:422-429
[11] He Y, Lian W, Ding L, Fan X, Ma J, Zhang QY, et al. Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites. Arch Toxicol 2021;95:103-116
[12] Song Z, He Y, Ma J, Fu. PP, Lin G. Pulmonary toxicity is a common phenomenon of pyrrolizidine alkaloids. J Environ Sci Health C 2020;38:124-140
[13] Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010;52:1829-1835
[14] Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-2778
[15] Mawdsley JE, Rampton DS. Psychological stress in IBD: New insights into pathogenic and therapeutic implications. Gut 2005;54:1481-1491
[16] Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-391
[17] Thaker AI, Shaker A, Rao MS, Ciorba MA. Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS). J Vis Exp 2012;67:e4100
[18] Williams JM, Duckworth CA, Vowell K, Burkitt MD, Pritchard DM. Intestinal preparation techniques for histological analysis in the mouse. Curr Protoc Mouse Biol 2016;6:148-168
[19] Nadatani Y, Watanabe T, Tanigawa T, Machida H, Okazaki H, Yamagami H, et al. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am J Pathol 2012;181:98-110
[20] Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481
[21] Gu J, Weng Y, Zhang QY, Cui HD, Behr M, Wu L, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: Impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895-25901
[22] Zhang QY, Fang C, Zhang J, Dunbar D, Kaminsky L, Ding X. An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 2009;37:651-657
[23] Fan X, Ding X, Zhang QY. Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model. Acta Pharm Sin B 2020;10:123-135
[24] Ruan J, Gao H, Li N, Xue J, Chen J, Ke C, et al. Blood pyrrole-protein adducts--A biomarker of pyrrolizidine alkaloid-induced liver Injury in humans. J Environ Sci Health C 2015;33:404-421
[25] DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999;29:1779-1791
[26] Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854
[27] Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006;1:3159-3165
[28] Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008;1:183-197
[29] Huxtable RJ, Yan CC, Wild S, Maxwell S, Cooper R. Physicochemical and metabolic basis for the differing neurotoxicity of the pyrrolizidine alkaloids, trichodesmine and monocrotaline. Neurochem Res 1996;21:141-146
[30] Mattocks AR, Jukes R. Trapping and measurement of short-lived alkylating-agents in a recirculating flow system. Chem Biol Interact 1990;76:19-30
[31] Chan PC, Mahler J, Bucher JR, Travlos GS, Reid JB. Toxicity and carcinogenicity of riddelliine following 13 weeks of treatment to rats and mice. Toxicon 1994;32:891-908
[32] Yang M, Ruan J, Fu PP, Lin G. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact 2016;243:119-126
[33] Spolarics Z. Endotoxin stimulates gene expression of ROS-eliminating pathways in rat hepatic endothelial and Kupffer cells. Am J Physiol 1996;270:G660-G666
[34] Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003;66:1499-1503
[35] He Y, Zhu L, Ma J, Wong L, Zhao Z, Ye Y, et al. Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environ Pollut 2020;267:115542
[36] Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2015;11:CD001176
[37] van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113:383-389
[38] Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-173
[39] Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B 2016;6:374-383
[40] Yang M, Ma J, Ruan J, Zhang C, Ye Y, Pi-Cheng Fu P, et al. Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides - mechanism and its potential toxic impact. J Ethnopharmacol 2020;249:112421
[41] Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009;50:638-644
[42] Altin JG, Bygrave FL. Non-parenchymal cells as mediators of physiological responses in liver. Mol Cell Biochem 1988;83:3-14
[43] Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009;27:147-163
[44] Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006;43:S54-S62
[45] Knook DL, Sleyster EC. Isolated parenchymal, Kupffer and endothelial rat liver cells characterized by their lysosomal enzyme content. Biochem Biophys Res Commun 1980;96:250-257
[46] Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997;322:567-573
[47] Masubuchi Y, Enoki K, Horie T. Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos 2008;36:597-603
[48] Dai J, Zhang F, Zheng J. Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4. Chem Biol Interact 2010;183:49-56
[49] Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95
Similar articles:
1.Xiaoyu Fan, Xinxin Ding, Qing-Yu Zhang.Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model[J]. Acta Pharmaceutica Sinica B, 2020,10(1): 123-135
Similar articles: